Literature DB >> 15780488

Therapeutic value of antidepressants in asthma.

G Krommydas1, K I Gourgoulianis, K Karamitsos, K Krapis, E Kotrotsiou, P A Molyvdas.   

Abstract

Laboratory and clinical data provide evidence that a biological linkage exists between asthma and depression. Cytokines are key molecules in both diseases. They promote allergic reaction as well as depressive symptomatology. Antidepressants may have a therapeutic role in asthma by suppressing production of proinflammatory cytokines, inducing production of anti-inflammatory ones and preventing their brain effects. Most antidepressants also induce adaptive changes in central monoaminergic neurotransmission, which itself might modulate immune reactivity and central actions of cytokines. Antidepressants may also have direct effects on the immune cells. Their impact on hypothalamus-pituitary-adrenal axis is discussed. Antidepressants are expected to terminate the cascade of inflammatory events in other inflammatory diseases as well. The use of antidepressants in experimental clinical trials in patients with asthma is suggested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780488     DOI: 10.1016/j.mehy.2004.06.036

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

Review 1.  Stress and allergic diseases.

Authors:  Ninabahen D Dave; Lianbin Xiang; Kristina E Rehm; Gailen D Marshall
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

Review 2.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Stephanie L Prady; Justyna Pollok; Adrian J Esterman; Andrea L Gordon; Simon Knowles; Jane M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2019-04-12

4.  Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.

Authors:  Antonina Mikocka-Walus; Patrick A Hughes; Peter Bampton; Andrea Gordon; Melissa A Campaniello; Chris Mavrangelos; Benjamin J Stewart; Adrian Esterman; Jane M Andrews
Journal:  J Crohns Colitis       Date:  2017-04-01       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.